Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease
You‐Ri Kang(National Cancer Center), Hyung-Soo Lee(Seoul Medical Center), Ha Young Shin(Yonsei University), Tai‐Seung Nam(Chonnam National University Hospital), Woojun Kim(National Cancer Center), Sooyoung Kim(Ulsan College), Byung‐Jo Kim(Korea University), Eun Hee Sohn(Chungnam National University), In Soo Joo(Ajou University), Hyunjin Ju(Samsung Medical Center), Byeol‐A Yoon(Kyungpook National University Hospital), Sukyoon Lee(Inje University Busan Paik Hospital), Young‐Min Lim(Ulsan College), Young Nam Kwon(Yonsei University), Jee‐Eun Kim(Ewha Womans University), Jin‐Woo Park(Korea University), Hyunjin Kim(Samsung Medical Center), Sung‐Min Kim(Ulsan College), Su Hyun Kim(Centre National de la Recherche Scientifique), Min-Su Park(National Medical Center), Ho Jin Kim(National Cancer Center), Seung Woo Kim(Seoul National University), Jong-Kuk Kim(Dong-A University), Sun‐Young Oh(Inje University Busan Paik Hospital), Ki Hoon Kim(Inje University Sanggye Paik Hospital), Woohee Ju(Chung-Ang University Hospital), Ju‐Hong Min(Samsung Medical Center), Jae-Won Hyun(National Cancer Center), Seung Ho Choo(Samsung Medical Center), Eun-Jae Lee(Asan Medical Center)
Cited by 5
Related Papers
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
Neuromyelitis optica
|Nature Reviews Disease Primers|2020|464
Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder
|Multiple Sclerosis Journal|2011|284